Latest Oncology News

No abstract available... Read more
Published on: 2021-01-22
Source: TOPICS IN PAIN MANAGEMENT - latest articles
No abstract available... Read more
Published on: 2021-01-22
Source: TOPICS IN PAIN MANAGEMENT - latest articles
No abstract available... Read more
Published on: 2021-01-22
Source: TOPICS IN PAIN MANAGEMENT - latest articles
Napierh Stephen... Read more
Published on: 2021-01-22
Source: JOURNAL OF CLINICAL RESEARCH & BIOETHICS - table of contents
Michele Scialpi, Aldo Di Blasi, Longo Ferdinando... Read more
Published on: 2021-01-22
Source: JOURNAL OF VACCINES & VACCINATION - table of contents
Sabiha Noor, Shabnam Sambyal, Saif Ismail, Narendra Chirmule... Read more
Published on: 2021-01-22
Source: JOURNAL OF VACCINES & VACCINATION - table of contents
Prakash Chandra Arya, Priyanka Bajaj... Read more
Published on: 2021-01-22
Source: JOURNAL OF VACCINES & VACCINATION - table of contents
Amalia T Utami, Andhika B Prasetya... Read more
Published on: 2021-01-22
Source: JOURNAL OF VACCINES & VACCINATION - table of contents
Phillip Lee , John Moss... Read more
Published on: 2021-01-22
Source: JOURNAL OF VACCINES & VACCINATION - table of contents
Published on: 2021-01-22
Source: JOURNAL OF THE NATIONAL CANCER INSTITUTE - podcast
By: Oxford University Press
Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types. Tumorous PD-L1 expression, as assessed by immunohistochemistry (IHC), is an accepted predictive marker of response to therapy in some cancers. However, expression is often dynamic and heterogeneous, and... Read more
Published on: 2021-01-22
Source: JOURNAL FOR IMMUNOTHERAPY OF CANCER - recent issues
By: Kelly, M. P., Makonnen, S., Hickey, C., Arnold, T. C., Giurleo, J. T., Tavare, R., Danton, M., Granados, C., Chatterjee, I., Dudgeon, D., Retter, M. W., Ma, D., Olson, W. C., Thurston, G., Kirshner, J. R.
Purpose Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can function as predictive biomarkers for anti-PD1±anti-CTLA4 ICI in patients with advanced melanoma. Methods... Read more
Published on: 2021-01-22
Source: JOURNAL FOR IMMUNOTHERAPY OF CANCER - recent issues
By: Rose, A. A. N., Armstrong, S. M., Hogg, D., Butler, M. O., Saibil, S. D., Arteaga, D. P., Pimentel Muniz, T., Kelly, D., Ghazarian, D., King, I., Kamil, Z. S., Ross, K., Spreafico, A.

Other Resources

Oncology Videos

Watch the selected videos

Other News by Specialization

Other News by Specialization

Citations

Latest Citations

Latest News

Latest News

Translate »